WELL Health
Trending >

Xebec Adsorption has a 65 per cent upside, says M Partners

Xebec Adsorption

Updated guidance from cleantech company Xebec Adsorption (Xebec Adsorption Stock Quote, Chart TSX:XBC) is no cause for concern, says M Partners analyst Andrew Hood, who on Friday reiterated his “Buy” recommendation and $2.20 target price.

Ahead of Xebec’s full year 2018 financials due on April 17, management announced on Thursday that it had updated its guidance for 2018 and 2019 due to the application of a new IFRS 15 accounting standard, which requires the company to forego recognition of revenues as a percentage of completion and calls for the company to wait until completion of projects occurs. As a result, $5.5 million in revenues expected to be accounted for in Q4 2018 are now pushed to 2019.

Hood says the impact is effectively nil.

“It is important to understand that this change in guidance merely reflects proper accounting measures and shifts revenues and earnings a couple quarters into the future. As a result, we are maintaining our valuation of $2.20/share based on 18.0x 2020 EBITDA,” he said.

The analyst is calling for 2018 revenue and EBITDA of $20 million and negative $2.1 million, respectively, and 2019 revenue and EBITDA of $51 million and $6.6 million, respectively. His $2.20 target represents a return of 65 per cent at the time of publication.

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

About The Author /

Jayson is a writer, researcher and educator with a PhD in political philosophy from the University of Ottawa. His interests range from bioethics and innovations in the health sciences to governance, social justice and the history of ideas.
insta twitter facebook


Leave a Reply